| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The precise molecular target of WAY-640810 has not been fully elucidated. It is described as a chemical agent that may alter the lifespan of eukaryotes. The compound belongs to the class of organic compounds known as quinoline carboxamides, which are quinolines substituted by one or more carboxamide groups. Further research is needed to identify its specific biological targets.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for WAY-640810, such as IC50 values, have not been extensively reported in the available literature. It is primarily characterized as a research chemical for studying potential lifespan-modulating effects in eukaryotic systems.
|
| ln Vivo |
Specific in vivo activity data for WAY-640810 have not been extensively reported. The compound is used as a research tool for studying potential lifespan-extending effects in eukaryotic organisms. Further studies would be required to evaluate its in vivo efficacy.
|
| Enzyme Assay |
Specific protocols for enzyme/receptor binding assays for WAY-640810 are not detailed in the available literature. As a research chemical, its activity would typically be assessed using target-specific binding assays appropriate for its suspected mechanism of action in lifespan modulation studies.
|
| Cell Assay |
Specific protocols for in vitro cellular assays for WAY-640810 are not detailed in the available literature. Cellular activity would typically be evaluated in relevant eukaryotic cell lines to assess effects on cell viability, proliferation, or other phenotypic markers related to lifespan modulation.
|
| Animal Protocol |
Specific protocols for in vivo animal studies for WAY-640810 are not detailed. In vivo evaluation would typically involve administration to model organisms such as yeast, worms, or mice to study effects on lifespan and healthspan parameters.
|
| ADME/Pharmacokinetics |
WAY-640810 has a molecular formula of C22H18N4OS and a molecular weight of 386.47. Its chemical name is 2-pyridin-4-yl-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)quinoline-4-carboxamide. It is typically stored as a solid at room temperature and is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for WAY-640810 are not available in the cited literature. The compound is intended for research use only and not for human therapeutic applications. Standard laboratory safety precautions should be followed when handling this compound.
|
| Additional Infomation |
WAY-640810 was first reported in patent document US20090163545. It is a research chemical used for studying potential lifespan-modulating effects in eukaryotes. The compound belongs to the quinoline carboxamide class and is a valuable tool for basic research into aging and longevity pathways.
|
| Molecular Formula |
C22H18N4OS
|
|---|---|
| Molecular Weight |
386.47
|
| Exact Mass |
386.12
|
| Elemental Analysis |
C, 68.37; H, 4.69; N, 14.50; O, 4.14; S, 8.30
|
| CAS # |
851206-31-0
|
| PubChem CID |
2462581
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
28
|
| Complexity |
555
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC2=C(C1)N=C(S2)NC(=O)C3=CC(=NC4=CC=CC=C43)C5=CC=NC=C5
|
| InChi Key |
FAJJOOSPYDZYFS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H18N4OS/c27-21(26-22-25-18-7-3-4-8-20(18)28-22)16-13-19(14-9-11-23-12-10-14)24-17-6-2-1-5-15(16)17/h1-2,5-6,9-13H,3-4,7-8H2,(H,25,26,27)
|
| Chemical Name |
2-(4-Pyridinyl)-N-(4,5,6,7-tetrahydro-2-benzothiazolyl)-4-quinolinecarboxamide
|
| Synonyms |
WAY-640810; WAY 640810; WAY640810;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5875 mL | 12.9376 mL | 25.8752 mL | |
| 5 mM | 0.5175 mL | 2.5875 mL | 5.1750 mL | |
| 10 mM | 0.2588 mL | 1.2938 mL | 2.5875 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
